A Study of Molecular Residual, Dynamic Monitoring and Recurrence of Stage III Driver Mutated NSCLC

Más betegség

• Patients with other malignancies within 5 years
• According to the investigator, the patient also had other diseases that may affect the follow-up and short-term survival

Laborértékek

• The subject had other factors that may lead to the termination of the study, such as other serious diseases (including mental illness), serious laboratory abnormalities, and family or social factors that affected the safety of the subject, or the collection of data and samples

• Patients with stage III non-small cell lung cancer were confirmed by imaging and histological biopsy
• Age≥ 18
• ECOG PS:0-1
• Tumor molecular testing by EBUS or biopsy confirmed positive for one or more of the following driver genes:EGFR\ALK\ROS1\RET\KRAS\PIK3CA\BRAF\HER2\MET
• Patients who met and agreed to surgery or radical chemoradiotherapy, and the remaining samples after cutting tissue sections did not affect the possible further clinical treatment of the subject
• Provide 20 mL peripheral blood samples periodically
• The subjects volunteered to join the study, and signed the informed consent form, with good compliance, and actively cooperated with the hospital for routine clinical diagnosis and treatment follow-up